Newcastle

Horizontal Tabs

Overview
Our Centre 

ECMC and CRUK Centre where the focus of research is the delivery of early phase trials in both adults and paediatric patients, with fully compliant dedicated early phase trials units and clinical pharmacology facilities.  The ECMC has experience in multiple first-in-human studies, including small molecules, immunotherapy, novel antibodies and cellular therapies

Our Patient Population
Catchment area population of ~3.5M, also regularly accepting out of region referrals for molecularly profiled studies, including from devolved nations and EU
Organisations affiliated with the Newcastle ECMC:
 
Our location
North East of England with catchment area of ~3.5M
Contact the Centre Manager:
Chris Barron
christopher.barron@nhs.net
+44 (0) 191 213 8435
Address 

Northern Institute for Cancer Research
University of Newcastle Upon Tyne
The Medical School
Framlington Place
Newcastle Upon Tyne NE2 4HH

Great North Children’s Hospital
Royal Victoria Infirmary
Queen Victoria Road
Newcastle upon Tyne NE1 4LP

Team Members
Centre Lead

Professor of Experimental Cancer Medicine and Lead for ECMC and CRUK centre as well as director of trials facility.  Academic medical oncologist running phase I practice and also treating skin cancer, laboratory research projects into cancer drug toxicity and skin cancer

More
Image of Alastair Greystoke
Centre Co-Lead
+44 (0)191 213 8466

Dr Alastair Greystoke joined Newcastle University and the Northern Centre for Cancer Care in 2014. He is one of three consultants that run the Sir Bobby Robson Early Clinical Trials Centre at the Freeman Hospital in Newcastle, and has a special interest in the development of new anti-cancer drugs for patients with thoracic malignancies. In addition he is the Clinical Lead for Cancer for the Yorkshire, Hull and North East England Genomic Laboratory Hub, the Joint Chief Investigator of the CONCORDE platform (adding in new drugs to radical radiotherapy in lung cancer), and leads the Pharmacodynamic Biomarker team at Newcastle University

More
Centre Business Lead

ECMC manager and manager of early phase trials unit

More
PPIE (Patient and Public Involvement and Engagement) Lead

CRUK Senior Nurse, lead for PPIE and also nursing education

More

Scientific & Operational Team

Senior Lecturer
+44 (0) 191 208 4332

Operational Team

Research Governance Manager
+44 (0)191 282 4823
Nurse
+44 (0) 191 213 8436
Consultant Radiologist
+44 (0) 191 282 4115
Early Phase Trial Coordinator
+44 (0) 191 213 8434
Senior Lead Clinical Trials Pharmacist
+44 (0) 191 282 4793
Biobank Contact
+44 (0) 191 208 7161
Adult Expertise
Treatment Modalities 
Immunotherapy
Small Molecules
Facilities/Translational Research 
  • Radiopharmacy
  • On-site pharmacy
  • PK testing facilities
  • Biobanking facilities
  • Dedicated research staff
  • Snap freezing facilities
  • On-site ITU (intensive treatment unit)
  • On-site central lab
  • Positive air-pressure in-patient rooms
Cancer Types
Newcastle ECMC has expertise across all solid tumours and haematological malignancies. Particular areas of research focus are gynaecological malignancies, thoracic malignancies, skin cancers, urological cancers, liver cancer, paediatric brain tumours and leukaemias

Extensive all comers solid tumour practice with >300 new patients per year referred from more than 50 consultants across the region, parallel supra-regional paediatric and haematology services for early phase trial delivery.  Programmatic and translational research funding within Newcastle Univeristy in gynaecological malignancies, thoracic malignancies, skin cancers, urological cancers, colorectal cancer, liver cancer and paediatric brain tumours and leukaemias, with biobanking of samples in these areas.

Drug/Treatment Modalities
  • Advanced cellular therapies
  • Combination therapies
  • Novel antibodies and antibody drug conjugates 

ECMC based in comprehensive regional cancer centres with apheresis, CAR-T, bone marrow transplant facilities as well as all standard cancer treatment modalities

Radiotherapy
We have regular access to photon beam radiotherapy. We have research expertise in the following:
  • Intensity Modulated Radiotherapy (IMRT)
  • Image Guided Radiotherapy (IGRT)
  • Stereotactic Radiotherapy (SBRT/SABR)
  • Radiosurgery
  • Internal Radiotherapy
  • Tomotherapy
  • SPECT and MRI planning available
Molecular Diagnostic Testing
We have NGS panel testing on tumour samples and ctDNA profiling available on a routine basis to our patients. This is offered to early phase trial referrals as standard. We are moving to ctDNA testing to link to TARGET National trial
Paediatric Expertise
Paediatric Expertise 

The Paediatric team is both part of the Newcastle ECMC with a specific focus to run early phase clinical trials for adolescents and young adults (AYA) across both sites; and part of the national paediatric ECMC Network.

It is also an accredited early phase clinical trials centre of the European network Innovative Therapies for Children with Cancer (ITCC). To further facilitate our ability to offer novel therapies to children and young people in the North we have recently founded an early phase clinical trials network with Glasgow, Edinburgh, Aberdeen and Belfast, the Phase I Northern ChiLDrEn’s Cancer Network (INCLuDE).  

Facilities to accommodate families who need to travel to Newcastle are available.

The Newcastle Cancer Centre hosts one of the largest translational research programmes in paediatric oncology (both leukaemia and solid tumours) in Europe. Our researchers have developed strong links with the CR-UK funded Newcastle Drug Discovery Programme and the Sir Bobby Robson Cancer Trials Research Centre to create new therapies against targets and develop trials in paediatric malignancies. The CR-UK funded paediatric tumour biobank is also housed in Newcastle.

The Newcastle Paediatric Centre is linked with Birmingham's Cancer Research UK Clinical Trials Unit.

 

 

 

Case Study
Case Studies 
MEDALLION-PILOT Study- a translational research trial

In 2019 the Newcastle ECMC successfully opened the MEDALLION-PILOT study, which is a translational research study run using ECMC resource where we are exploring the potential causes of toxicities seen in patients receiving immunotherapy treatment with the immune checkpoint inhibitors.  We plan to recruit up to 80 patients, having either combination or single agent immunotherapy.

The study asks patients to allow us to collect blood, skin swab and stool samples when they come to hospital for their immunotherapy treatment visits, and also if they need steroid treatment for any side effects.  The study was designed with input from our Early Phase trials PPI team, who were very supportive and felt that understanding the causes of side effects and hopefully being able to predict who might get them was a very important research question.  The toxicities which patients develop on checkpoint inhibitors mimics known auto-immune diseases such as inflammatory bowel disease, and rheumatoid arthritis and the MEDALLION-PILOT study team includesresearchers from these disciplines.

The study supports the research projects of 2 PhD students, one clinical and one scientific fellow, and is also designed to develop the pilot data to support an application for an Experimental Medicine Grant to run a larger multi-centre multi-disciplinary study with Glasgow, Oxford, Birmingham and Kings ECMCs. 

The impact of this study is likely to be important in two areas.  Firstly, we are trying to understand what factors may predict which patients develop toxicity, whether these are genetic, related to blood T-cell changes or environmental and related to skin or gut microbiome.  Understanding toxicity and its causes better will help us advice patients on risks and help us develop treatment strategies.  We also know that patients who develop more side effects are more likely to get a good response, so we hope to be able to identify signatures for this.  Secondly, as we are collecting sequential samples from patients over a number of months of their treatment we can map the course of any map the course of any temporal changes linked to auto-immune disease and potentially identify key factors that trigger its development.

ECMC resource is critical for this study as it supports sample collection and processing and also project management through our Translational Research Team.

First in human trial of Berzosetib

The Newcastle ECMC led the first-in-human, first-in-class study of Berzosertib, an inhibitor of ATR, a protein involved in the DNA damage response.  This was a collaboration initially with Vertex Pharmaceuticals and subsequently Merck KGA.  The Newcastle ECMC worked closely with Vertex in developing the protocol and led the study globally.  For the first part of the study all the study sites were ECMCs in the UK – Newcastle, Oxford, Glasgow and Manchester, with major US centres such as MD Anderson and Dana Faber joining for the later parts of the trial.

ATR is a protein involved in the repair of damaged DNA and the study’s primary aim was to find the safe dose to give to patients, what any side effects might be, and how Berzosertib might be safely combined with a number of chemotherapy drugs to try and improve their effectiveness.  This study completed recruitment in 2019, and established the safe single agent dose of Berzosertib and also safe doses in combination with 3 different chemotherapy regimens.  The importance of this research by the ECMC network is that we were recognised to have the skills and expertise to take a first-in-class agent into the clinic across the network sites, and the safety data and dose we found have been used in all subsequent studies of this agent.

The impact of this ECMC trial became clear even whilst the trial was still ongoing as the dosing data was used in a single agent study which showed that ATR inhibitors can have activity in tumours with certain mutations, without the need for chemotherapy. This is a much less toxic way to use this class of drugs and identifies a clinical development strategy for a number of other compounds in this class which are currently being developed.  In addition, the safe doses we established with chemotherapy have been taken forward in phase II studies, the results of one of these in ovarian cancer was highlighted at ESMO 2019 (DOI: 10.1016/S1470-2045(20)30180-7).

ECMC resource which supported this study funded research coordinators, research nurses and laboratory technicians who are all key parts of the early phase trials team.